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ABSTRACT 
Indan ring system, also known as indane or benzocyclopentane, is an important chemical 
feature associated with various biological activities. Among the drugs possessing an indan 
ring system, 1H-indene-3-acetic acid-5-fluoro-2-methyl-1-[4-(methylsulfinyl)-
phenyl]methylene (Sulindac) and 6-chloro-5-cyclohexyl indan-1-carboxylic acid (Clidanac) 
are well known anti-inflammatory agents, whilst indan-1,3-dione is an anticoagulant. Over 
the years, several indan derivatives, particularly indan acid derivatives, have been synthesized 
and their potential analgesic and anti-inflammatory properties have been studied. This review 
critically appraises various synthetic protocols and structure-activity-relationships of indan 
acids as analgesic and anti-inflammatory agents with low ulcerogenicity. 
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1. INTRODUCTION  
 
Indan (also known as indane or benzocyclopentane) ring system (Figure 1) is regarded as an 
ideal chemical feature associated with various biological activities [1-3]. Over the years, 
several indan derivatives have been synthesized with the expectation of generating 
pharmacologically active compounds as new drug candidates. Some of these compounds 
have eventually turned out to be pharmacologically active with any practical uses [1, 4]. 
 
Clidanac
6-Chloro-5-(cyclopentanylmethyl)indan-1-carboxylic acid
Indan ring system
 
Figure 1. Indan ring system, and some indan acid-based anti-inflammatory agents 
 
Many indan derivatives are indan acids, and they were synthesized as potential analgesic and 
anti-inflammatory agents [1, 5-15]. For example, the analogues of p-alkylphenylacetic acids 
and 5-alkyl-1-indan-carboxylic acids were synthesized as anti-inflammatory agents, and 
among them, 6-chloro-5-cyclohexyl-1-indancarboxylic acid was found to possess the highest 
level of analgesic, anti-inflammatory and antipyretic activities [16]. Later, 6-chloro-5-
cyclohexyl-1-indancarboxylic acid was introduced into the market as Clidanac as an anti-
inflammatory drug (Figure 1) [5, 7, 17]. However, this compound displayed significant 
ulcerogenicity along with anti-inflammatory activity at a dose of 400 mg/kg. Interestingly, an 
isomer of this compound, known as 6-chloro-5-(cyclopentanylmethyl)-indan-1-carboxylic 
acid (Figure. 1) displayed anti-inflammatory activity, but no detectable ulcerogenicity in the 
acute or chronic treatment models in rats and monkeys [7]. It was also noted that 1,2,3,4-
tetrahydro-1-naphthoic acid derivatives did not have potent activity as that of corresponding 
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1-indan-carboxylic acids [5, 17]. Apparently, 1-indan-carboxylic acid may have the essential 
conformation of the phenylacetic acids for exhibiting the anti-inflammatory activity.  
 
Ketoprofen (Figure 2), a meta-substituted aryl-aceitc acid derivative, was found to be an 
effective anti-inflammatory agent [18]. This finding gave birth to the hypothesis that a new 
anti-inflammatory agent could be obtained by introducing an appropriate substituent at either 
4- or 6-position of 1-indan-carboxylic acid, which corresponds to the meta-position in 
phenylacetic acid [19]. As a result, in the search for more potent, less toxic and new analgesic 
and anti-inflammatory agents, indan acids with various substitutions, e.g., halogenation or 
methoxylations, on the benzene ring of the indan nucleus have been synthesised [1, 5-15, 17, 
19]. 
 
 
Figure 2. Ketoprofen, a potent anti-inflammatory agent 
 
Electrophilic substitutions, particularly, halogenations on the indan nucleus received 
considerable attention with respect to their relative reactivities and orientation on the 
aromatic ring [20]. The substitution takes place predominantly on the 6-position of the indan 
ring or 3-position of the starting materials benazaldehyde [10, 21]. Owing to electrochemical 
nature, halogens exert a pronounced influence on the biological behaviour of organic 
compounds. Thus, it was predicted that halo-substituted indan-1-acids should have similar 
activity profile as that of halo-substituted indole-3-acetic acid [1, 10, 12, 15, 21]. Pal et al. [1] 
carried out dichloro substitution at 5- and 6-positions of the indan ring with starting material 
3,4-dichlorobenzaldehyde, and evaluated the anti-inflammatory activity of the products. 
Since aromatic halogen substitution is a reasonable means of increasing the activity and 
widening the margin of safety, a number of chloro- and bromo-substituted analogues of 
indan-1-carboxylic acid and that of indan-1-acetic acid were synthesized to investigate the 
effect of halo-substitution on the biological activity of the indan-1-acids [1, 10, 12, 15, 21]. 
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Like halo-substitution, methoxy-substitution was also considered as an option for increasing 
the potency of indan acids. A number of methoxy-substituted indan derivatives were 
synthesized to evaluate various pharmacological activities like hypoglycemic, antilipidemic, 
analgesic, antipyretic and anti-inflammatory [22-28]. The methoxy-substitutions were found 
to exhibit necessary pharmacological activities and binding affinity at the melatonin receptor 
molecules [29]. The steric and the electronic properties of the substituent on the phenyl ring 
necessary for the receptor recognition were investigated by introducing different groups at the 
4-position on the ring for better activity. The effects of the position of chloro- or methoxy-
substitution on the resulting pharmacological activity were also evaluated [30].  
 
This review critically appraises various synthetic protocols and structure-activity-
relationships of indan acid derivatives as analgesic and anti-inflammatory agents with low 
ulcerogenicity. 
 
2. SYNTHESIS OF INDAN ACID DERIVATIVES 
 
2.1.  Indan acids 
2.1.1. Indan-1-carboxylic acids 
4-Chloroindan-1-carboxylic acid (4a), 5-chloroindan-1-carboxylic acid (4b), 6-chloroindan-
1-carboxylic acid (4c), 7-chloroindan-1-carboxylic acid (4d), 4-bromoindan-1-carboxylic 
acid (6b) and 6-bromoindan-1-carboxylic acid (6a) were synthesized by Aono et al. [19]. 
Different (chlorophenyl)-succinic anhydrides (2) were prepared from corresponding 
substituted (phenyl)-succinic acids (1), e.g., 2-(chlorophenyl)-succinic acid (1a), 3-
(chlorophenyl)-succinic acid (1b) and 4-(chlorophenyl)-succinic acid (1c), by refluxing with 
acetic anhydride (Scheme 1). The anhydrides (2) were subjected to the Friedel-Crafts 
acylation to afford 5-chloro-3-oxo-indan-1-carboxylic acid (3a), 6-chloro-3-oxo-indan-1-
carboxylic acid (3b) and 7-chloro-3-oxo-indan-1-carboxylic acid (3c). 4-Chloro-3-oxo-indan-
1-carboxylic acid (3d) was obtained as a by-product of 3b from its organic layer (CH2Cl2-
CHCl3 mixture) after washing it with water, extracted with Na2CO3 (5%) and finally acidified 
with dil. HCl. The 3-oxo derivatives (3) were then reduced to the respective acids (4) using 
the Clemmensen reaction (Scheme 1).  
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Acetic anhydride
AlCl3Friedel-Craft acylation
2
1
Clemmensen reduction
34
 
Scheme 1. Synthesis of various chloroindan-1-carboxylic acids 
 
Aono et al. [19] also reported the synthesis of chloroindan-1-carboxylic acids (4a-d) using a 
different synthetic approach (Scheme 2). Chlorination of indan-1-carboxylic acid (5) 
produced these compounds. To a stirred, ice-cooled mixture of 5 and catalyst (FeCl3, TiCl4, 
ZnCl2 and SnCl4), Cl2 solution was added drop-wise. The mixtures were stirred for 1.3 h 
under cooling and then poured into ice-water. The mixtures were extracted with ether, 
washed with water, dried over anhydrous MgSO4 and evaporated to dryness. Similarly, 6-
bromoinadan-1-carboxylic acid (6a) was prepared by bromination in presence of catalyst, and 
4-bromoindan-1-carboxylic acid (6b) was obtained as a by-product (Scheme 2).  The indan-
1-carboxylic acid (5) could easily be synthesized by hydrogenation of indene-1-carboxxylic 
acid (7) using the Raney nickel catalyst [31] (Scheme 2).   
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Cl2 or Br2 / Lewis acid
Hydrigenation
Raney Ni
5
7
Catalyst
4   X = Cl 
6   X = Br
 
Scheme 2. Synthesis of various haloindan-1-carboxylic acids 
 
6-Fluoroindan-1-carboxylic acid (13a), 6-chloroindan-1-carboxylic acid (4c) and 6-
bromoindan-1-carboxylic acid (6a), 5,6-dichloroindan-1-carboxylic acid (13b), 6-
methoxyindan-1-carboxylic acid (13c) and 5,6-dimethoxyindan-1-carboxylic acid (13d) were 
synthesized starting from respective substituted benzaldehydes (8) [1, 12, 21, 22] (Scheme 3). 
The substituted benzaldehydes (8) were reacted with ethylcyanoacetate in dry benzene (C6H6) 
in presence of pyridine (C5H5N) and glacial acetic acid (AcOH). The reaction mixtures were 
refluxed in an oil bath, and then evaporated to dryness under reduced pressure. The solid 
residues, substituted-phenyl cyanoacrylic esters (9), were filtered, washed sequentially with 
water, HCl (5%) and cold water, dried and crystallized in aqueous ethanol (EtOH).  The 
substituted-phenyl cyanoacrylic esters (9) were allowed to react with sodium cyanide (NaCN) 
using water as a solvent. The reaction mixtures were refluxed in presence of 50% aqueous 
EtOH, cooled, poured in water, conc. HCl was added to it and kept for overnight. The 
mixtures were then extracted three times with chloroform (CHCl3). The individual extract 
was washed with water, dried over baked sodium sulphate and evaporated to dryness. The 
products, substituted-phenyl α,β-dicyanoethylpropionates (10), were hydrolyzed by refluxing 
with conc. HCl to obtain corresponding substituted-phenyl succinic acids (11), separated as a 
white solid on cooling. The white solids were then filtered, washed with cold water, dried and 
re-crystallized from hot water. The respective diacids (11) were converted to diacylchlorides 
by refluxing them with thionylchloride (SOCl2) in dry C6H6. The benzene and excess SOCl2 
were removed under vacuum to obtain diacylchlorides as liquid. Anhydrous aluminium 
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chloride was poured immediately into the reaction mixtures of diacylchlorides in portion wise 
in well stirred condition using carbon disulfide (CS2) as a solvent. The reaction mixtures were 
stirred at r.t., and decomposed in ice water mixture. CS2 was evaporated on a hot water bath. 
The 3-oxo compounds (12) precipitated after cooling of the mixtures, filtered, washed 
thoroughly with water, dried and re-crystallized. The respective 3-oxo-indan-1-carboxylic 
acids (12) were reduced to corresponding substituted indan-1-carboxylic acids (4c, 6a, 13a-d) 
following the Clemmensen reduction. The compounds were separated from the reaction 
mixture through solvent extraction.  
 
Ethylcyanoacetate, dry C6H6
C5H5N, glacial AcOH
NaCN
Acid hydrolysis
AlCl3 or polyphosphoric acid
Zn-Hg/HCl
98
R = Cl, Br, F or OMe
R' = H, Cl or OMe 
1011
12 4c     R = Cl; R' = H
6a     R = Br; R' = H
13a   R = F;R' = H
13b   R = R' = Cl
13c   R = OMe; R' = H
13d   R = R' = OMe  
Scheme 3. Synthesis of various halo- and methoxyindan-1-carboxylic acids from respective 
substituted benzaldehydes 
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An improved method for the synthesis of various substituted indan-1-carboxylic acid 
derivatives involved cyclization of phenyl succinic acid and reduction of the indanon-1-
carboxylic acid with triethylsilane in trifluoroacetic acid. However, the synthesis was not 
targeted toward generation of new anti-inflammatory or analgesic compounds [32]. Fujimura 
et al. [33] synthesized 6-chloro-5-cyclohexyl-1-indancarboxylic acid as an anti-inflammatory 
agent. Similarly, several 5-substituted 1-indancarboxylic acids were prepared as potential 
anti-inflammatory agents [34]. 
 
2.1.2. Indan-1-acetic acids 
The synthesis of several substituted indan-1-acitic acids (17a-f) has been reported [1, 15, 21, 
22] (Scheme 4). The respective substituted benzaldehydes (8) were condensed with ethyl 
acetoacetate in 1:2 molar ratios in presence of piperidine allowing the reaction mixtures in 
anhydrous condition at r.t. After completion of the reaction, yellow solids were obtained. The 
solid masses were crushed, and washed with ether. The white crystalline powders were 
obtained and re-crystallized from acetone-water as substituted benzylidine-bis-acetoacetates 
(14), which were hydrolyzed by refluxing with alcoholic KOH solution. The alcohol was then 
distilled off under reduced pressure, diluted with water, washed with CHCl3 and neutralized 
by conc. HCl in cold condition with stirring. The precipitations thus formed as substituted β-
phenylglutaric acids (15), were filtered and re-crystallized from alcohol-water as crystalline 
solids. The respective diacids (15) were cyclized to substituted 3-oxo-indan-1-acetic acids 
(16) using polyphosphoric acid as dehydrating agent by heating at 120°C with stirring for 10-
15 min or anhydrous AlCl3 using CS2 as a solvent. The reaction mixtures were poured into 
ice-water mixture. The solids were filtered, washed with cold water and re-crystallized from 
aqueous EtOH. The compounds as substituted-3-oxo-indan-1-acetic acids (16) were then 
subjected to the Clemmensen reduction using C6H6. The benzene layers were washed with 
water and dried over anhydrous magnesium sulphate (MgSO4). After removal of the solvent 
under reduced pressure, the target compounds (17a-f) were obtained. The products were re-
crystallized from aqueous EtOH.  
 
Similarly, a series of indan acetic acid derivatives were synthesized as potential selective 
insulin sensitizers [35, 36]. Zhang et al. [37] reported the enantio-selective synthesis of an 
indan acetic acid derivative, methyl (2S)-2-[(1S)-5-hydroxy-2,3-dihydro-1H-inden-1-yl]-
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butanoate. The main indene acetic acid framework was constructed via a robust, 
unprecedented Reformatsky process. One stereogenic center was set via a resolution, and the 
other via a diastereoselective hydrogenation of the indene acetic acid. However, the synthesis 
was not linked to any pharmacological activity assessment. 
Ethylacetoacetate
Piperidine
Alkali hydrolysis
Polyphosphoric acid or
i) SOCl2, C6H6
ii) AlCl3, CS2
Zn-Hg/HCl
17a     R = R' = H
17b     R = F; R' = H
17c     R = Cl; R' = H
17d     R = Br; R' = H
17e     R = R' = Cl
17f      R = R' = OMe
17g     R = OMe; R' = H
8
14
15
16
 
 
Scheme 4. Synthesis of substituted indan-1-acetic acids 
 
2.1.3. Indan-1-propionic acids and indan-1-butyric acids   
Mukhopadhyay et al. [28] synthesized several long-chain indan acid analogues, 2-(indan-1-
yl)-propionic acid (21a), 2-(6-methoxyindan-1-yl)-propionic acid (21b), 2-(5,6-
dimethoxyindan-1-yl)-propionic acid (21c), 3-(indan-1-yl)-butyric acid (21d), 3-(6-
methoxyindan-1-yl)-butyric acid (21e), and 3-(5,6-dimethoxyindan-1-yl)-butyric acid (21f),  
by the consecutive Arndt-Eistert reaction starting from respective indan-1-acids (18a-f) 
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(Scheme 5). The Arndt-Eistert reaction is a series of chemical reactions designed to convert a 
carboxylic acid functionality to a higher carboxylic acid homologue (i.e., contains one 
additional carbon atom) and is considered a homologation process. In indan-1-acids the 
increased aliphatic chain length could separate the hydrophobic indan ring system from the 
pharmacophoric carboxyl group.  
 
Indan-1-acetic acid (18a), 6-methoxyindan-1-acetic acid (18b) and 5,6-dimethoxyindan-1-
acetic acid (18c) were refluxed with SOCl2 to obtain various indan-1-acetyl chlorides (19), 
which were then dissolved in dry ether, added slowly to a cold ethereal solution of 
diazomethane (CH2N2) under reflux. The mixtures were stirred continuously and kept below 
5°C during addition, and allowed to stand overnight at r.t. Ether was distilled off under 
reduced pressure, indan-1-actyl diazoketone, 6-methoxyindan-1-actyl diazoketone and 5,6-
dimethoxyindan-1-actyl diazoketone were dissolved in MeOH, and a slurry of silver oxide 
(prepared from AgNO3 and NaOH) in MeOH was added in portions at 30-40°C, and the 
progress of reactions were followed by N2 evolution. When the addition was over, 
temperature of the bath was raised to 60-70°C and the mixture was refluxed for 0.5 h. The 
solutions were boiled with charcoal, filtered and the methanolic solution was concentrated. 
The resulting esters (20) were extracted in ether, washed consecutively with dil. HCl, alkali 
and water, dried and distilled under reduced pressure. The esters were refluxed with 10% 
KOH solution for 3 h. MeOH was removed and the aqueous layer washed with ether, and the 
resulting 3-(indan-1-yl)-propionic acid (21a), 3-(6-methoxyindan-1-yl)-propionic acid (21b) 
and 3-(5,6-dimethoxyindan-1-yl)-propionic acid (21c) were precipitated with dil. HCl. The 
precipitated acids were re-crystallized from alcohol-water. 4-(Indan-1-yl)-butyric acid (21d), 
4-(6-methoxyindan-1-yl)-butyric acid (21e) and 4-(5,6-dimethoxyindan-1-yl)-butyric acid 
(21f) were synthesized following the same procedure as outlined above, but using the starting 
materials 3-(indan-1-yl)-propionic acid (18d), 3-(6-methoxyindan-1-yl)-propionic acid (18e) 
and 3-(5,6-dimethoxyindan-1-yl)-propionic acid (18f), respectively (Scheme 5).   
 
Several non-methoxy and methoxyindan-1-propionic acids, as potential anti-
hypercholesterolemic agents, were synthesized also from their corresponding benzaldehyde 
via indan-1-acetic acid as an intermediate [38]. 3-(5,6-Dimethoxyindan-1-yl)-propionic acid 
(18f) showed better activity profile than their homologues, but none of them was found to be 
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superior to standard drug Clofibrate (Figure 3). Earlier, the same group also synthesized 
trimethoxy analogs of indan-1-acetic acid [39] and alpha-alkyl substituted derivatives [40]. 
Witiak et al. [41] reported the synthesis of indan-propionic acids as uterine relaxants. 
 
Figure 3. Structure of Clofibrate 
 
SOCl2 in C6H6
i. CH2N2 in ether
ii. Ag2O, methanol
10% KOH, H2O
18a     R = R' = H; n = 1
18b     R = OMe; R' = H; n = 1
18c     R = R' = OMe; n = 1
18d     R = R' = H; n = 2
18e     R = OMe; R' = H; n = 2
18f      R = R' = OMe; n = 2
19
2021a     R = R' = H; n = 1
21b     R = OMe; R' = H; n = 1
21c     R = R' = OMe; n = 1
21d     R = R' = H; n = 2
21e     R = OMe; R' = H; n = 2
21f     R = R' = OMe; n = 2
 
Scheme 5. Synthesis of substituted indan-1-propionic and butyric acids 
 
2.2. Indan acid derivatives with extra heterocyclic rings 
The respective acids (22) were treated with SOCl2 to prepare acid chlorides, which were 
treated immediately with NH3 solution at 1-5°C to afford respective amides (23) in excellent 
yields. The amides (23) were dehydrated with P2O5 in dry C6H6 or in a mixture of POCl3 and 
NaS2O5 (10:1 ratio) by refluxing for 2-4 h. After decomposing the reaction mixtures and 
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working up, the respective nitriles (24) were obtained. Subsequently, the nitriles were 
allowed to react with activated NaN3 in presence of NH4Cl in DMF at 130-140°C for 48 h to 
afford the target tetrazole derivatives (25a–f) and (26a-f) as crystalline solids [1, 10, 27, 42, 
43] (Scheme 6).  
 
ii. NH4OH, C6H6, 1-5oC
i. SOCl2, C6H6, heat, 1.5 h
22
R'' = COOH or CH2COOH
P2O5 or POCl3 and Na2O5
Dry C6H6, 1.5 h
NaN3, NH4Cl
DMF, 130-140oC, 48 h
25a     R = R' = H
25b     R = Cl; R' = H
25c     R = Br; R' = H
25d     R = R' = Cl
25e     R = OMe; R' = H
25f      R = R' = OMe
or
24
R'' = CN or CH2CN
23
R'' = CONH2 or CH2CONH2
26a     R = R' = H
26b     R = Cl; R' = H
26c     R = Br; R' = H
26d     R = R' = Cl
26e     R = OMe; R' = H
26f     R = R' = OMe
 
Scheme 6. Synthesis of indan acid derivatives with extra heterocyclic rings 
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3. ANALGESIC ACYTIVITY OF INDAN ACID DERIVATIVES AND THEIR 
STRUCTURE-ACTIVITY-RELATIONSHIPS 
 
The analgesic activity of compounds 6-fluoroindan-1-carboxylic acid (13a) (Scheme 3) was 
assessed by the acetic acid induced writhing in Swiss albino mice [12], and this compound 
was found to significantly reduce the writhing induced by acetic acid in a dose dependent 
manner. 6-Fluoroindan-1-carboxylic acid (13a) exhibited ~22% inhibition at the dose of 25 
mg/kg body weight and 36% inhibition at the dose of 50 mg/kg body weight. Another indan 
acid derivative, 6-fluoroindan-1-acetic acid (17b), showed 38% inhibition at the dose of 25 
mg/kg body weight and 47% inhibition at the dose of 50 mg/kg body weight [15]. From these 
findings, it could be suggested that an increase in carbon number, i.e., acetic acid (-
CH2COOH as in 17b) [15] instead of a carboxylic acid (-COOH in 13a) [12] functionality, 
might have contributed to the increased analgesic potency of compound 17b. The analgesic 
activity of these fluoroindan acids was comparable to those of the positive controls, e.g., 
Aminopyrine, Indomethacin and Diclofenac (Figure 4). 
 
Aminopyrine Indomethacin Diclofenac  
Figure 4. Structures of Aminopyrine, Indomethacin and Diclofenac 
 
Indan acids, e.g., indan-1-carboxylic acid (5), 6-methoxyindan-1-carboxylic acid (13c), 5,6,-
dimethoxyindan-1-carboxylic acid (13d), indan-1-acetic acid (17a), 5,6,-dimethoxyindan-1-
acetic acid (17f), were also screened for analgesic activity [12, 15, 25].  Roy et al. [25] 
evaluated the analgesic activity of various indan acids using the phenylquinone-induced 
writhing in mice at varying dose levels. Generally, the indan-1-carboxylic acid derivatives (5, 
13c and 13d), exhibited less potent analgesic effects than corresponding indan-1-acetic acids, 
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e.g., 17a and 17f.  It was also observed that the introduction of a methoxy group at 6 or both 
at 5- and 6-positions of indan-1-acetic acid enhanced remarkably the analgesic activity. 
 
Mukhapadhyay and Lahiri [8] observed the analgesic activity of 3-(indan-1-yl)-propionic 
acid (21a), 3-(6-methoxyindan-1-yl)-propionic acid (21b), 3-(5,6-dimethoxyindan-1-yl)-
propionic acid (21c), 4-(indan-1-yl)-butyric acid (21d), 4-(6-methoxyindan-1-yl)-butyric acid 
(21e) and 4-(5,6-dimethoxyindan-1-yl)-butyric acid (21f) in phenyl-p-quinone induced 
writhing in mice (Scheme 5). It was noted that indiscriminate chain lengthening was not 
necessarily beneficial to biological activity. Among the compounds, 21a, 21b and 21c 
exhibited analgesic activity at a dose of 200 mg/kg body weight, which was comparable to 
that of phenylbutazone.  
 
The analgesic activity of 5,6-dichloroindan-1-carboxylic acid (13b) and 5,6-dichloroindan-1-
acetic acid (17e) was measured by the acetic acid-induced writhing in Swiss albino mice [1]. 
The analgesic activity, exhibited by 13b with the doses of 50 and 100 mg/kg body weight, 
appeared to be better than that of the reference compounds, Phenylbutazone, Indomethacin 
and Aminopyrine (Figure 4), with the doses of 100, 50 and 30 mg/kg body weight, 
respectively. With the dose of 25 mg/kg body weight, 13b exhibited almost similar potency 
to that of Indomethacin. 5,6-Dichloroindan-1-acetic acid (17e) at the doses of 50 and 100 
mg/kg weight, also showed good therapeutic activity, but was less than that of 13b. This 
investigation showed that both compounds (13b and 17e) had good peripheral analgesic 
activity with the doses of 25, 50 and 100 mg/kg body weight, and thus concluded that 
introduction of chloro-functionalities at 5- and 6-positions of the indan nucleus could increase 
the analgesic activity compared to that of mono chloro-substituted nucleus, e.g., 6-
chloroindan-1-carboxylic acid (4c). At the same time, it was noted that an increase in carbon 
number, i.e., acetic acid (-CH2COOH as in 17c) instead of a carboxylic acid (-COOH in 4c) 
functionality, decreased the analgesic potency of the compound. 
 
Ray and Lahiri [42-44] reported the analgesic activity of 5-(indan-1’-yl)-tetrazole (25a), 5-
(6’-methoxyindan-1’-yl)-tetrazole (25e) and 5-(5’,6’-dimethoxyindan-1’-yl)-tetrazole (25f) in 
the phenyl-p-quinone induced writhing reflex in mice model. All three compounds exhibited 
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variable analgesic activities with, respectively, 28.2%, 25.3% and 20.7% protection in 
comparison to reference standard Phenylbutazone (52.2% protection) and Aspirin (60.2% 
protection). Significant analgesic activity was also observed with other tetrazole derivatives, 
5-(indan-1′-yl)-methyltetrazole (26a), 5-(6′-methoxyindan-1′-yl)-methyltetrazole (26e) and 5-
(5′,6′-dimethoxyindan-1′-yl)-methyltetrazole (26f) in the phenyl-p-quinone induced 
preliminary test with low ulcerogenecity [44]. The ED50 dose for 26e and 26f were 
determined 117 and 166 mg/kg (p.o.), respectively, compared to positive control 
Phenylbutazone (41 mg/kg) [44]. However, the compounds did not show any response in the 
hot plate and the tail clip methods. From these studies [26, 27, 42, 43], it could be concluded 
that the introduction of a methoxy group at 6 or both at 5- and 6-positions of the compounds, 
as well as an increase of one carbon between the indan nucleus and tetrazole group increases 
the activity. 
 
The analgesic activity of 5-(5′,6′-dichloroindan-1′-yl)-tetrazole (25d) and 5-(5′,6′-
dichloroindan-1′-yl)-methyltetrazole (26d) was assessed by the acetic acid-induced writhing 
in Swiss albino mice [1]. The significant (p < 0.001) analgesic activity, exhibited by the 
compound 25d with the doses of 50 and 100 mg/kg body weight, was better than that of the 
reference compounds, Phenylbutazone, Indomethacin and Aminopyrine, with the doses of 
100, 50 and 30 mg/kg body weight, respectively. The methyltetrazole derivative 26d also 
displayed good therapeutic activity at 50 and 100 mg/kg weight, but was less potent than that 
of 25d. This finding also suggested that an introduction of a chloro group at both 5- and 6- 
positions of the indan nucleus could increase the analgesic activity compared to that of mono 
chloro substitution only at 6-position. At the same time, it could also be inferred that an 
increase in carbon number between indan nucleus and tetrazole ring i.e., 5-(5′,6′-chloroindan-
1′-yl)-methyltetrazole (26d), could decrease the analgesic potency of the compound.  The 
structural features of indan acid derivatives that influence the analgesic potency of these 
compounds can be summarized as follows (Figure 5). 
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Fig. 5e OMe OMe -CH2-COOH 
Fig. 5f OMe H -(CH2)n-tetrazolyl 
Fig. 5g OMe OMe -(CH2)n-tetrazolyl 
 
Figure 5. Summary of structural features of indan acid derivatives that influence the 
analgesic potency 
 
i. An increase in carbon number on the acid functionality increases the analgesic 
potency of indan-1-acids (refer to R’’ on Figure 5a). However, indiscriminate 
chain lengthening may not be beneficial to activity. 
ii. For chloroindan-1-acids, an increase in carbon number on the acid decreases the 
analgesic potency (refer to R’’ on Figure 5b).  
iii. An introduction of chloro functionality both at 5- and 6-positions (Figure 5c) of 
the indan nucleus increases the analgesic activity compared to that of mono chloro 
substituted nucleus (Figure 5b). 
iv. An introduction of a methoxy group at 6 (Figure 5d) or both at 5- and 6-positions 
(Figure 5e) of indan-1-acetic acid enhances the analgesic activity remarkably. 
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v. In indanyl tetrazoles, an introduction of a methoxy group at 6 (Figure 5f) or both 
at 5- and 6-positions (Figure 5g) of the indan nucleus, as well as an increase of 
one carbon between the indan nucleus (refer to R’’ on Figures 5f and 5g) and 
tetrazole group increases the activity. 
 
The writhing reflex in mice induced by acetic acid and phenylquinone is a sensitive 
procedure to evaluate the potential analgesic activity of drugs. It has been suggested that 
acetic acid and phenylquinone act by releasing endogenous mediators, which stimulate the 
nociceptive neurons in mice. Acetic acid is sensitive to cyclooxygenase inhibitors and has 
been used to evaluate the effect of analgesic agents, which primarily inhibit the 
cyclooxygenase involved in prostaglandin synthesis. Acetic acid and phenylquinone are also 
sensitive to non-steroidal anti-inflammatory drugs (NSAIDs) and to narcotics and other 
centrally acting drugs. Recently it has been found that the nociceptive activity of acetic acid 
and phenylqinone may be due to the release of cytokines, such as TNF-α, interleukin-1β and 
interleukin-8, by resident peritoneal macrophages and mast cells. Based on this, it can be 
assumed that in the antinociceptive action showed by compounds in the acetic acid and 
phenylquinone induced writhing test might be due to inhibition of the release of TNF-α, 
interleukin-1β and interleukin-8, by resident peritoneal macrophages and mast cells. The 
writhing response observed after the treatment with various indan derivatives was assumed to 
be mediated through peritoneal mast cell [45], acid sensing ion channels [46] and the 
prostaglandin pathways [47]. 
 
4. ANTI-INH;AMMATPRY ACTIVITY OF INDAN ACID DERIVATIVES, AND 
THEIR STRUCTURE-ACTIVITY-RELATIONSHIPS 
 
The anti-inflammatory activity of indan-1-carboxylic acids (4-6, 13a-d) was evaluated for 
anti-inflammatory activity in the carrageenan induced rat paw edema model. The reference 
standards Indomethacin, Aspirin, Diclofenac and Phenylbutazone were used as standard drug 
and saline as control. Juby et al. [5] reported that indan-1-carboxylic acid (5) did not possess 
any significant anti-inflammatory activity. It was observed that 6-chloroindan-1-carboxylic 
acid (4c), 6-bromoindan-1-carboxylic acid (6c) [unpublished work of Paul and Bachar] and 
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5,6-dichloroindan-1-carboxylic acid (13b) [1] had statistically significant anti-inflammatory 
response with respect to inhibiting paw edema in comparison to control in a dose dependent 
manner. The percent inhibition of edema volume at the dose of 50 mg/kg body weight by the 
compounds 4c, 6c and 13b, after the third hour of carrageenan administration, was 19.18%, 
16.12% and 44.51%, respectively. Slightly better activity was exhibited by the compounds 6-
chloroindan-1-acetic acid (17c), 6-bromoindan-1-carboxylic acid (17d) [unpublished work of 
Paul and Bachar] and 5,6-dichloroindan-1-acetic acid (17e) with  percent inhibitions of 
19.82%, 18.25% and 34.91%, respectively [1]. It could be suggested from this finding that a 
substitution at 6-position of the indan ring with a chloro or a bromo functionality could 
enhance the anti-inflammatory potency of indan acids. Chloro substitution at both 5- and 6- 
positions, e.g., 5,6-dichloroindan-1-carboxylic acid (13b), showed slightly better activity than 
that of 5,6-dichloroindan-1-acetic acid (17e), indicating that increase of carbon length 
decreases the anti-inflammatory potency of indan acids.  
 
Lahiri and Gupta [22] synthesized 6-methoxy and 5,6-dimethoxy-indan-1-acids (13d and 17f) 
as potential oral hypoglycemic agents.  Later, the anti-inflammatory activity of 13d and 17f 
as well as other indan acids was studied using the doses of 100 and 200 mg/kg body weight in 
animal model [23, 24]. The activity was compared after the third hour of the study for 200 
mg/kg body weight. Among the compounds indan-1-acetic acid (17a) displayed better anti-
inflammatory potency than that of indan-1-carboxylic acid (5). 6-Methoxyindan-1-carboxylic 
acid (13c, 47.32% inhibition) and 5,6-methoxy-indan-1-carboxylic acid (13d, 33.65% 
inhibition) showed less anti-inflammatory activity than 6-methoxyindan-1-acetic acid (17g, 
51.13% inhibition) and 5,6-dimethoxyindan-1-acetic acid (17f, 56.35% inhibition). On the 
basis of the above findings, further investigations were carried out with 17g and 17f in 
various acute, sub-acute and chronic inflammation models including the carrageenan induced 
rat paw edema, kaolin-induced rat paw edema, formalin induced rat paw edema, 5-
hydroxytryptamine induced edema, cotton-pellet granuloma and adjuvant-induced arthritis 
[23-25]. Both compounds showed the highest level of activity at the third hour of the study 
and significant activity of the compounds were observed even at 24 h after the drug 
administration in comparison to Phenylbutazone. This longer duration of action of those 
indan acid derivatives might be due to their rapid binding to the plasma protein and 
subsequent slow release when the unbound acids having high pKa values (6.66 to 6.74) as 
slowly dissociated to their anions which were expected to be the pharmacophore [49].  From 
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this finding it was concluded that a methoxy substitution at 5- and 5, 6-positions with one 
carbon increased between indan ring and tetrazole functional group could be essential for 
better anti-inflammatory activity.  
 
The anti-inflammatory activity was also studied with the compounds, 3-(indan-1-yl)-
propionic acid (21a), 3-(6-methoxyindan-1-yl)-propionic acid (21b), 3-(5,6-dimethoxyindan-
1-yl)-propionic acid (21c), 4-(indan-1-yl)-butyric acid (21d), 4-(6-methoxyindan-1-yl)-
butyric acid (21e) and 4-(5,6-dimethoxyindan-1-yl)-butyric acid (21f) on the carrageenan 
induced rat paw edema model along with indan-1-carboxylic acids (Scheme 3) and indan-1-
acetic acids (Scheme 4) [1, 15, 26]. It was observed that indiscriminate chain lengthening did 
not enhance the potency of anti-inflammatory activity, as the activity appeared to reside in a 
small structural framework. The anti-inflammatory activity was more prominent in indan-1-
acetic acids, e.g., indan-1-acetic acid (17a, 42.88% inhibition), 6-methoxyindan-1- acetic acid 
(17f, 55.22% inhibition) and 5,6,-dimethoxyindan-1- acetic acid (17g, 54.91% inhibition), 
and indan-1-propionic acids, e.g., indan-1-propionic acid (21a, 40.14% inhibition), 3-(6-
methoxyindan-1-yl)-propionic acid (21b, 54.91% inhibition) and 3-(5,6-dimethoxyindan-1-
yl)-propionic acid (21c, 57.54% inhibition). The indan-1-carboxylic acids, e.g., indan-1-
carboxylic acid (5, 28.83% inhibition), 6-methoxyindan-1-carboxylic acid (13c, 40.11% 
inhibition) and 5,6,-dimethoxyindan-1-carboxylic acid (13d, 43.56% inhibition),  and indan-
1-butyric acids, e.g., 4-(indan-1-yl)-butyric acid (21d, 30.19% inhibition), 4-(6-
methoxyindan-1-yl)-butyric acid (21e, 48.12% inhibition) and 4-(5,6-dimethoxyindan-1-yl)-
butyric acid (21f, 52.18% inhibition), exhibited less activity. This indicated that one carbon 
separation between the indan ring and the carboxylic acid functionality is probably the 
optimum feature for anti-inflammatory activity of indan acid; less or more carbon than one 
seems to reduce the activity. The anti-inflammatory activity in this series could also be 
potentiated by the incorporation of methoxyl substitutions at 5- and 6-positions of the indan 
nucleus. It was found that the onset of action of these compounds were relatively slow, 
compared to that of Phenylbutazone; the anti-inflammatory activity of these compounds 
reached its peak after 3 h of their oral administration and in some cases was retained even 
after 24 h. 
 
Page | 22  
 
The non-steroidal anti-inflammatory activity of the indan-1-propionic acid derivatives (21a-
c) were found to be dose dependant, and was comparable to that of Phenylbutazone in the 
carrageenan induced rat paw edema model [8]. The inhibition of paw oedema appeared to be 
its maximum level at the third hour of the study. Among these compounds, 3-(6-
methoxyindan-1-yl)-propionic acid (21b) and 3-(5,6-dimethoxyindan-1-yl)-propionic acid 
(13c) showed better anti-inflammatory activity in the Kaolin induced paw edema and the 
immunological (granuloma) models [8], indicating the importance of the methoxy 
substituent(s) on the indan nucleus for this activity. Compounds 21b and 21c exhibited better 
anti-inflammatory potency in the cotton pellet granuloma study, particularly at lower dose 
levels, than that of Phenylbutazone. They exhibited high LD50 values with low 
ulcerogenecity, specially the compounds 21c due to its more lipophilic nature. 
 
The anti-inflammatory activity of chloro-and bromo-substituted (indanyl)-tetrazoles, e.g., 5-
(6′-chloroindan-1′-yl)-tetrazole (25b) and 5-(6′-bromoindan-1′-yl)-tetrazole (25c), and 
(indanyl)-methyltetrazoles, e.g., 5-(6′-chloroindan-1′-yl)-methyltetrazole (26b) and 5-(6′-
bromoindan-1′-yl)-methyltetrazole (26c) was evaluated in the carrageenan-induced rat paw 
edema model at the dose of 100 mg/kg of body weight  [10, 49]. Compounds 26b (39.98% 
inhibition) and 26c (33.06% inhibition) showed better activity than that of 25b (19.66% 
inhibition) and 25c (18.15% inhibition), indicating the significance of one carbon separation 
between the tetrazole and the indan moieties for better anti-inflammatory profile. The 
percentage inhibitions produced by compounds were compared with that of the positive 
control phenylbutazone. Compounds 26b and 26c were further studied at the dose of 50 
mg/kg, where promising activity was exhibited by 26b, suggesting that a chloro as opposed to 
a bromo substitution contributes more to the anti-inflammatory potency of indanyl-tetrazole 
compounds. Other indanyl-tetrazole derivatives, e.g., 5-(indan-1′-yl)-tetrazole (25a) and 5-
(6′-methoxyindan-1′-yl)-tetrazole (25e) and 5-(5′,6′-dimethoxyindan-1′-yl)-tetrazole (25f) 
were also assessed for anti-inflammatory activity, and at the third hour of study the percent 
inhibitions caused by these compounds were 28.03%, 6.79% and 12.84%, respectively [42, 
43]. Similar studies on the indan-methyltetrazole derivatives, e.g., 5-(indan-1′-yl)-
methyltetrazole (26a) and 5-(6′-methoxyindan-1′-yl)-methyltetrazole (26e) and 5-(5′,6′-
dimethoxyindan-1′-yl)-methyltetrazole (26f), revealed that 26e (37.08% inhibition) and 26f 
(41.51% inhibition) had more potent activity than that of 26a (24.35% inhibition) [26, 27]. 
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The compounds showed dose dependent activity in both the carrageenan induced oedema and 
the adjuvant-arthritis test models.  
 
Roy and Lahiri [44] further studied the anti-inflammatory, analgesic, anti-pyretic activities, 
gastric ulcerogenicity and acute lethal toxicity of 5-(6′-methoxyindan-1′-yl)-methyltetrazole 
(26e) and 5-(5′,6′-dimethoxyindan-1′-yl)-methyltetrazole (26f). It was observed that the ED50 
values of 26e in the adjuvant arthritis and the cotton pellet granuloma models were almost 
similar to that of Phenylbutazone. Pal et al. [1] synthesized 5-(5′,6′-dichloroindan-1′-yl)-
tetrazole (25d) and 5-(5′,6′-dichloroindan-1′-yl)-methyltetrazole (26d) and evaluated the anti-
inflammatory activity in the carrageenan induced rat paw edema model with the doses of 25 
and 50 mg/kg body weight. A significant (p < 0.001) anti-inflammatory activity was observed 
with 25d at the dose of 50 mg/kg body weight, and was comparable to that of reference 
standard Phenylbutazone (dose of 100 mg/kg body weight) after 3 h of carrageenan 
administration. Compound 26d with the doses of 25 and 50 mg/kg body weight also 
displayed almost similar anti-inflammatory activity as that of Phenylbutazone in 1, 2 and 3 h 
after carrageenan administration. It was concluded that the introduction of a chloro 
substituent both at 5- and 6-positions of the indan nucleus could increase the anti-
inflammatory activity more than just one chloro substitution at 6-position.  
 
The structural features of indan acid derivatives that influence the anti-inflammatory potency 
of these compounds can be summarized as follows (Figure 6). 
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Figure 6. Summary of structural features of indan acid derivatives that influence the anti-
inflammatory potency 
 
i. Halogenation on the indan nucleus of indan-1-carboxylic acid offers increased 
anti-inflammatory potency, e.g., a substitution at 6-position of the indan ring with 
a chloro or a bromo functionality enhances the anti-inflammatory potency of 
indan acids (Figure 6a). 
ii. Halogenation at both 5- and 6-positions of the indan nucleus slightly increases 
potency (Figure 6b). 
iii. In haloindan-1-acids (Figure 6c), an increase of carbon length (refer to R’’ on 
Figure 6c) decreases the anti-inflammatory potency. 
iv. In methoxyindan-1-acids (Figure 6d), an increase of carbon length (refer to R’’ on 
Figure 6d) increases the anti-inflammatory potency. 
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v. Methoxy substitution at 5- (Figure 6e) and 5, 6-positions (Figure 6f) with one 
carbon increased between indan ring and tetrazole functional group (refer to R’’ 
on Figures 6e and 6f) is essential for better anti-inflammatory activity.  
vi. One carbon separation between the tetrazole and the indan moieties is essential for 
better anti-inflammatory profile (refer to R’’ on Figures 6e and 6f). 
 
5. CONCLUSIONS 
Various synthetic protocols for the synthesis of bromo-, chloro-, fluoro- and methoxy-
derivatives of indan-1-carboxylic, indan-1-acetic, indan-1-propionic and indan-1-butyric 
acids, as well as of indanyl-tetrazole and indanyl-methyltetrazole have been reported to date. 
The analgesic and anti-inflammatory properties of these derivatives have been studied in 
vivo, mainly using various rat models. From those studies, some patterns of structure-activity-
relationships, e.g., the importance of the substituents on the indan nucleus or the carbon 
length of acids, related to analgesic and anti-inflammatory properties have begun to emerge.  
However, there is no report on any in vitro mechanistic studies involving various enzymes, 
e.g., COX-1 and COX-2, available to date, and thus, much work is probably needed in this 
area to have a clear understanding about the mechanism of action of these indan-based 
promising analgesic and anti-inflammatory compounds. 
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